ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EBS vs CAPR // GROSS PROFIT MARGIN

Emergent BioSolutions Inc. (NYSE) VS. Capricor Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EBS 3 — CAPR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. CAPR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EBS CAPR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 56.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 8.90% -35.00% +43.90 EBS /roic <GO>
EV/EBITDA & P/E Valuation 6.6x — — TIE /valuation <GO>
Free Cash Flow Yield — -18.86% — TIE /fcf-yield <GO>
Operating Margin 13.50% — — TIE /operating-margins <GO>
Net Profit Margin 7.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) -28.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.41 3.38 -1.97 CAPR /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 EBS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.0 41.6 +11.38 EBS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.5x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $370.2M $385.5M -$15.3M CAPR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EBS REV CAPR REV EBS GROSS % CAPR GROSS % EBS FCF CAPR FCF
FY 2025 $742.9M $0 56.1% — $156.8M -$72.7M
FY 2024 $1.04B $22.3M 34.7% — $35.8M -$41.2M
FY 2023 $1.05B $25.2M — — -$206.3M -$25.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
CAPR // BETA —